NCT00587873View on ClinicalTrials.gov

Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 1994

Primary Completion Date

December 31, 2003

Study Completion Date

June 30, 2009

Conditions
Hodgkin's Disease
Interventions
DRUG

Methotrexate

MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion

DRUG

Leucovorin calcium

5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.

DRUG

6-Thioguanine

6-TG 300 mg/m2 PO as a single oral dose

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00587873 - Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II) | Biotech Hunter | Biotech Hunter